Aimei Health Technology Co., Ltd - Ordinary Share

Short‑term asset value is reasonably anchored by cash and T‑bills in the trust account with a disclosed per‑share redemption value of 11.80 dollars at March 31, 2026, rising modestly with monthly extension deposits and interest. Long‑term cash flows are wholly unpredictable because no operating target is in place and prior deal was terminated.

The SPAC has a finite life up to 36 months from the December 6, 2023 IPO, implying an outside date of December 6, 2026 absent a completed merger.